Ventripoint Diagnostics Ltd. is pleased to announce that it has received the European CE Mark for the VMS+ Whole Heart Analysis System, which allows the Company to begin selling the VMS+ throughout the European Union. This system uses conventional 2D ultrasound to analyse all four chambers of the heart in minutes with accuracy equivalent to MRI.
“This is great news as it allows the Company to bring the capabilities of the VMS+ to cardiologists in Europe and improve cardiac care,” stated Dr. George Adams, CEO of Ventripoint. “The quick acceptance of the VMS+ application is a credit to our development and regulatory groups.”
According to the European Heart Network, cardiovascular disease (CVD) causes 3.9 million deaths in Europe annually and accounts for 45 percent of all deaths in Europe. In 2015, there were just under 11.3 million new cases of CVD in Europe and more than 85 million people in Europe were living with CVD. Overall CVD is estimated to cost the European economy Euro 210 billion (USD 300B) a year.
The CE Mark is also recognized worldwide and will allow the Company to register the VMS+ in many additional regions and countries. This will greatly expand the commercial opportunities and allow distributors to sell into their regions. – Medical Buyer Bureau